Obstetric nursing reference: maternal care guide for nursing students

Obstetric (OB) nursing is one of the most high-stakes clinical rotations in nursing school. You are simultaneously caring for two patients – the laboring mother and the fetus – and the conditions that arise can deteriorate rapidly. This reference covers the core concepts tested on NCLEX and encountered in clinical practice: labor stages, fetal heart rate interpretation, hypertensive disorders of pregnancy, postpartum assessment, and the OB medications every nurse must know cold. Whether you are prepping for your OB rotation or studying for boards, this guide gives you the clinical framework you need.

Quick reference: key OB conditions

Stages of labor

Understanding the four stages of labor – and what nursing actions are expected at each stage – is foundational for your OB rotation and appears frequently on NCLEX.

Stage 1: dilation and effacement

Stage 1 begins with the onset of regular contractions and ends with full cervical dilation (10 cm). It is divided into three phases:

Latent phase (0–6 cm): Contractions are mild, 5–30 minutes apart, lasting 30–45 seconds. This phase is the longest and its length varies widely. It is traditionally called prolonged after 20 hours in a nullipara (first-time mother) or 14 hours in a multipara, and ACOG Clinical Practice Guideline No. 8 (2024) notes that more than 16 hours may be used for nulliparas. Nursing interventions include assessing maternal vital signs, establishing IV access, reviewing the birth plan, and providing comfort measures. Continuous electronic fetal monitoring or intermittent auscultation per facility protocol.

Active phase (6–10 cm): Contractions intensify to moderate-to-strong, 3–5 minutes apart, lasting 45–60 seconds. Contemporary labor data show that dilation often speeds up after 6 cm, and the older Friedman minimum rates (1.2 cm/hour nullipara, 1.5 cm/hour multipara) are no longer used to diagnose a problem. Active-phase arrest is defined as dilation of at least 6 cm with ruptured membranes and no cervical change for 4 hours or more with adequate contractions, or 6 hours or more of inadequate contractions despite oxytocin (ACOG CPG 8). Nursing priorities shift to frequent fetal heart rate assessment, pain management (epidural placement, breathing techniques), repositioning for comfort and fetal oxygenation, and monitoring for complications.

Transition (8–10 cm): The most intense phase – contractions are every 2–3 minutes, lasting 60–90 seconds, often with an urge to push. The patient may feel overwhelmed or panicked. Stay present, provide strong coaching, and assess for complete dilation before allowing pushing.

Stage 2: pushing and delivery

Stage 2 spans from complete dilation (10 cm) to delivery of the infant. ACOG Clinical Practice Guideline No. 8 (2024) defines a prolonged second stage as more than 3 hours of pushing in a nullipara or more than 2 hours in a multipara, whether or not an epidural is in place. The older thresholds that added an hour for epidurals are no longer the ACOG standard. ACOG also recommends that pushing begin when complete dilation is reached. Nursing responsibilities: support effective pushing efforts (open-glottis vs. directed pushing per provider/patient preference), continuous fetal monitoring, prepare delivery equipment, and be ready to support the provider at delivery. Assess APGAR score at 1 and 5 minutes after birth.

Stage 3: placental delivery

Stage 3 begins after infant delivery and ends with delivery of the placenta, typically within 5–30 minutes. Signs of placental separation: gush of blood, lengthening of the umbilical cord, and the uterus rising and becoming globular. Do not apply cord traction before separation occurs – this can cause uterine inversion. Oxytocin is routinely administered after delivery to promote uterine contraction and reduce hemorrhage risk.

Stage 4: recovery (first 1–2 hours postpartum)

Stage 4 covers the immediate recovery period, usually the first 1–2 hours after delivery of the placenta. Nursing assessments every 15 minutes for the first hour, then per protocol. Key focus areas: uterine tone and position, vital signs (hemorrhage can present as tachycardia before a BP drop), lochia assessment, perineal integrity, bladder distension (a full bladder displaces the uterus and contributes to atony), and pain management. Skin-to-skin contact and breastfeeding initiation are promoted during this stage.

Fetal heart rate monitoring

Electronic fetal monitoring (EFM) is used in most U.S. labor and delivery units. Interpreting the fetal heart rate (FHR) strip is a core NCLEX skill – you must be able to identify patterns and know the appropriate nursing response.

Baseline FHR

Normal baseline FHR is 110–160 beats per minute (bpm). Assessed over a 10-minute window, excluding accelerations and decelerations. Tachycardia (>160 bpm) may indicate maternal fever, fetal infection, or hypoxia. Bradycardia (<110 bpm) may indicate umbilical cord compression, hypotension, or fetal compromise.

Accelerations

Abrupt increases in FHR of ≥15 bpm above baseline lasting ≥15 seconds (≥10 bpm for ≥10 seconds before 32 weeks). Accelerations are a reassuring sign of fetal well-being – they indicate an intact autonomic nervous system. No intervention required.

Decelerations

Decelerations are decreases in FHR below baseline and are classified by their timing relative to contractions:

Early decelerations: Gradual, uniform decreases that mirror contractions (onset-to-nadir ≥30 seconds). Caused by head compression during contractions. Benign – no intervention needed.

Late decelerations: Gradual decreases that begin after the peak of a contraction and return to baseline after the contraction ends. Caused by uteroplacental insufficiency – the placenta cannot deliver enough oxygen during peak uterine pressure. Late decelerations are the most NCLEX-critical finding. Nursing response: reposition left lateral (increases placental perfusion), reduce or stop oxytocin if running, give an IV fluid bolus, correct maternal hypotension, notify provider, and prepare for possible expedited delivery if the pattern does not respond. ACOG Clinical Practice Guideline No. 10 (2025) recommends against routine maternal oxygen for Category II or III tracings unless the patient is hypoxic.

Variable decelerations: Abrupt decreases (onset-to-nadir <30 seconds) that vary in timing and shape. Caused by umbilical cord compression. Occasional variables are common and often benign. If they are recurrent (with half or more of contractions), deep, or prolonged, reposition the patient (side-to-side, hands-and-knees), check for cord prolapse with a vaginal exam, and notify the provider, who may order amnioinfusion. See the VEAL CHOP mnemonic for a complete memory aid.

Category I/II/III classification (NICHD)

• Category I (normal): Baseline 110–160 bpm, moderate variability, accelerations present, no late or variable decelerations. Continue routine monitoring.
• Category II (indeterminate): Any pattern not Category I or III. Requires increased surveillance, evaluation, and possibly intrauterine resuscitation measures.
• Category III (abnormal): Sinusoidal pattern OR absent variability with recurrent late decelerations, recurrent variable decelerations, or bradycardia. Requires immediate evaluation and intervention – may indicate severe fetal compromise requiring emergency delivery.

Hypertensive disorders of pregnancy

Hypertensive disorders were recorded in 15.9% of US delivery hospitalizations in 2019, up from 13.3% in 2017 (CDC MMWR, 2022), and are a leading cause of maternal and perinatal morbidity. Nurses must distinguish between the conditions and know the pharmacologic management.

Gestational hypertension

BP ≥140/90 mmHg on two readings at least 4 hours apart after 20 weeks gestation, without proteinuria or other end-organ findings. Managed with close monitoring; can progress to preeclampsia.

Preeclampsia

Preeclampsia is diagnosed when gestational hypertension is accompanied by any of the following: proteinuria (≥300 mg/24-hour urine or protein:creatinine ratio ≥0.3), or in the absence of proteinuria, any of: thrombocytopenia (platelets <100,000/µL), impaired liver function (AST/ALT twice the upper limit of normal), new renal insufficiency (creatinine >1.1 mg/dL or doubled), pulmonary edema, new-onset headache unresponsive to medication, or visual symptoms (ACOG PB 222).

Severe features include: BP ≥160/110 on two readings 4 hours apart (sooner if antihypertensives are started), platelets <100,000/µL, liver enzymes twice normal or severe persistent RUQ/epigastric pain, creatinine >1.1 mg/dL or doubled without other cause, pulmonary edema, new headache unresponsive to medication, or visual disturbances.

Nursing priorities: position patient in left lateral decubitus (reduces aortocaval compression), institute seizure precautions (padded side rails, suction and O2 at bedside, dim lighting, minimize stimulation), continuous fetal monitoring, strict intake and output, deep tendon reflexes (DTRs) assessment, and magnesium sulfate administration. Review our full HELLP syndrome guide for overlapping diagnosis criteria.

Eclampsia

A new-onset tonic-clonic seizure in a patient with a hypertensive disorder of pregnancy and no other cause. It can occur before, during, or after birth; most postpartum cases occur within 48 hours, but later onset is possible. During a seizure: protect the airway, do not restrain, position left lateral, time the seizure, administer magnesium sulfate IV bolus (4–6 g over 15–20 minutes) per order, apply oxygen, and notify the provider immediately.

HELLP syndrome

HELLP – Hemolysis, Elevated Liver enzymes, Low Platelets – is a severe complication of preeclampsia. Laboratory findings: LDH >600 IU/L, AST/ALT elevated, platelets <100,000/µL. Symptoms include RUQ or epigastric pain, nausea, vomiting, and malaise. Risk of DIC, hepatic rupture, and maternal death. The only definitive treatment is delivery. Monitor for signs of coagulopathy and internal bleeding.

Magnesium sulfate

Magnesium sulfate is the drug of choice for seizure prophylaxis in preeclampsia with severe features and for treating eclamptic seizures.

• Loading dose: 4–6 g IV over 15–20 minutes
• Maintenance: 1–2 g/hr continuous infusion
• Therapeutic range: 4–7 mEq/L

Toxicity signs (assess before each dose or hourly):

• Loss of patellar (knee-jerk) DTRs – first sign of toxicity (occurs at 7–10 mEq/L)
• Respiratory depression (<12 breaths/min)
• Oliguria (<30 mL/hr)
• Flushing, somnolence

Antidote: Calcium gluconate 1 g IV over 3 minutes – must be at the bedside whenever magnesium is infusing. Stop the magnesium infusion if toxicity is suspected.

Postpartum assessment and hemorrhage

BUBBLE-HE assessment

The structured postpartum assessment covers: Breasts, Uterus, Bladder, Bowel, Lochia, Episiotomy/perineum, Homans’ sign (now largely replaced by calf tenderness + swelling assessment), and Emotional status. See the full BUBBLE-HE assessment guide for step-by-step technique.

Fundal assessment

Assess uterine tone and position at every postpartum check. The fundus should be:

• Immediately after delivery of the placenta: Firm and midline, about midway between the umbilicus and the symphysis or near the umbilicus
• Within about 12 hours: Rises to the umbilicus or up to 1 cm above it
• Day 1 onward: Descends 1 cm/day (involution), reaching below the symphysis pubis by day 10–14

A boggy (soft) uterus indicates uterine atony – the leading cause of postpartum hemorrhage. Firm with massage. A uterus displaced to the right suggests bladder distension – have the patient void or catheterize before re-assessing tone.

Lochia progression

• Lochia rubra (days 1–3): Red, blood-like, may contain small clots. Heavy flow (saturating more than one pad/hour) is abnormal.
• Lochia serosa (days 4–10): Pink to brown, thinner.
• Lochia alba (days 11–28): Yellow-white, mucoid.

A return to red bleeding after lochia has lightened can follow overexertion, but persistent or heavy bleeding needs to be reported, because it can signal subinvolution or retained placental fragments. Foul odor at any stage suggests endometritis.

Postpartum hemorrhage (PPH)

ACOG Practice Bulletin No. 183 (reaffirmed 2024) defines PPH as cumulative blood loss ≥1,000 mL, or blood loss accompanied by signs or symptoms of hypovolemia, within 24 hours of birth, regardless of route. The older split (≥500 mL vaginal, ≥1,000 mL cesarean) is no longer the ACOG definition, though loss above 500 mL after a vaginal birth still warrants closer monitoring. PPH is the leading cause of maternal mortality worldwide.

The 4 T’s of PPH causes:

Approximate shares from Evensen et al., American Family Physician 2017. ACOG PB 183 puts atony at 70–80%.

Nursing interventions for uterine atony:

1. Fundal (external uterine) massage by the nurse – the first action; bimanual compression is performed by the provider
2. Oxytocin 10–40 units in 500–1,000 mL IV fluid as a continuous infusion (or 10 units IM)
3. Methylergonovine (Methergine) 0.2 mg IM – contraindicated in hypertension and preeclampsia
4. Carboprost (Hemabate) 0.25 mg IM – avoid in asthma
5. Misoprostol 600–1,000 mcg oral, sublingual, or rectal
6. Tranexamic acid 1 g IV over 10 minutes, ideally within 3 hours of birth, when initial uterotonic therapy fails (PB 183; WOMAN trial)
7. Escalate to surgical interventions (uterine balloon tamponade, B-Lynch suture, hysterectomy) if pharmacologic measures fail

Establish two large-bore IV lines, draw type and crossmatch, activate massive transfusion protocol if indicated, and call for help early.

Common OB medications

Oxytocin (Pitocin)

Used for labor induction and augmentation, and to prevent/treat postpartum hemorrhage. Administered IV via infusion pump, titrated to achieve adequate contractions (about 3–5 contractions per 10 minutes, each lasting 40–60 seconds). Side effects: uterine tachysystole (more than 5 contractions in 10 minutes, averaged over 30 minutes), FHR changes, water intoxication (antidiuretic effect at high doses). Nursing priority: if tachysystole occurs, reduce or stop the infusion per protocol, reposition, give an IV fluid bolus, and notify the provider; oxygen is reserved for maternal hypoxia (ACOG CPG 10).

Magnesium sulfate

Covered in full detail above (hypertensive disorders section). Critical NCLEX rule: always assess DTRs, respiratory rate, and urine output before administering each dose. Calcium gluconate must be at the bedside.

Betamethasone (Celestone)

A corticosteroid given to accelerate fetal lung maturity. ACOG Committee Opinion No. 713 (with its interim update; reaffirmed 2024) recommends a course when birth is likely within 7 days at 24 0/7–33 6/7 weeks, says it may be considered from 22 0/7 weeks if resuscitation is planned, and allows a single course at 34 0/7–36 6/7 weeks for patients who have not had one (excluding pregestational diabetes). Dose: 12 mg IM every 24 hours for two doses. Reduces incidence of neonatal respiratory distress syndrome (RDS), intraventricular hemorrhage, and necrotizing enterocolitis. Monitor maternal blood glucose – corticosteroids cause transient hyperglycemia, which is clinically significant in patients with diabetes – and monitor the newborn for hypoglycemia after a late preterm course.

Misoprostol (Cytotec)

A prostaglandin E1 analogue used for cervical ripening, labor induction, and postpartum hemorrhage management. Administered vaginally, sublingually, buccally, or rectally depending on indication. Not recommended in patients with a prior uterine scar due to risk of uterine rupture.

RhoGAM (Rh immunoglobulin)

Administered to Rh-negative mothers to prevent sensitization to Rh-positive fetal red blood cells. Given at 28 weeks gestation and within 72 hours of delivery if the neonate is Rh-positive. Also indicated after miscarriage, ectopic pregnancy, amniocentesis, or any procedure with potential for fetomaternal hemorrhage. RhoGAM does NOT treat a mother who is already sensitized – it only prevents sensitization.

NCLEX priority concepts

These are the highest-yield OB topics on the NCLEX-RN. Know these cold.

Late decelerations = uteroplacental insufficiency. First action is to reposition the patient to the left lateral position, then stop or reduce oxytocin if infusing, give an IV fluid bolus, and notify the provider. Current ACOG guidance (CPG 10, 2025) reserves supplemental oxygen for maternal hypoxia, so an answer built around routine oxygen reflects older teaching. Late decelerations with absent variability are a Category III pattern requiring immediate intervention.

Magnesium toxicity protocol. Before starting magnesium sulfate and at least hourly during the infusion, assess all three: patellar DTRs (must be present), respiratory rate (must be ≥12 breaths/min), and urine output (must be ≥30 mL/hr). If any is absent or below threshold, stop the infusion and notify the provider. Antidote is calcium gluconate 1 g IV – it must be at the bedside.

Postpartum hemorrhage – first action. When the uterus is boggy (soft), the first nursing action is fundal massage (uterine massage). Start it immediately and call for help at the same time; if the uterus does not firm up and stay firm, uterotonics and further escalation follow.

Preeclampsia – priority assessment. When caring for a patient with preeclampsia, your top priority is assessing for signs of impending seizure: worsening headache, visual disturbances (photophobia, scotoma), RUQ epigastric pain, and hyperreflexia with clonus. Implement seizure precautions proactively, not reactively.

Placenta previa vs. abruptio placentae. Previa = painless, bright red bleeding (do not do a vaginal exam – it can precipitate catastrophic hemorrhage). Abruption = painful, dark red bleeding with a rigid abdomen. These presentations are tested together on NCLEX and the distinction drives completely different nursing actions.

Rh incompatibility and RhoGAM timing. RhoGAM must be given within 72 hours of delivery. An Rh-negative mother who delivers an Rh-positive infant and does not receive RhoGAM within 72 hours can develop antibodies that attack red blood cells in future Rh-positive pregnancies (hemolytic disease of the fetus and newborn).

APGAR scoring. Assessed at 1 and 5 minutes. Score of 7–10 is reassuring, 4–6 is moderately abnormal, and 0–3 is low. The score does not decide whether to start resuscitation: that decision is made at birth from breathing, tone, and heart rate, before the 1-minute score exists. See the full APGAR score nursing guide for complete scoring criteria.

For reference values relevant to OB lab work – platelets, BMP, liver enzymes – see our nursing lab values cheat sheet.

Related pages

• APGAR score nursing guide – scoring criteria and clinical decision points
• HELLP syndrome – detailed breakdown of diagnosis and management
• BUBBLE-HE assessment – full postpartum assessment checklist
• VEAL CHOP nursing mnemonic – fetal heart rate pattern interpretation
• Vital signs by age – normal ranges across the lifespan
• Nursing lab values cheat sheet – critical lab reference for OB and beyond
• Drug classifications for nursing – pharmacology overview including OB medications
• Hypertension nursing guide – blood pressure management principles

References

1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891
2. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Guideline No. 8: First and Second Stage Labor Management. Obstet Gynecol. 2024;143(1):144–162. doi:10.1097/AOG.0000000000005447 (Practice Bulletin No. 107, induction of labor, was formerly cited here; ACOG has withdrawn it.)
3. Resnik R, Lockwood CJ, Moore TR, Greene MF, Copel JA, Silver RM, eds. Creasy and Resnik’s Maternal-Fetal Medicine: Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2019.
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168–e186. doi:10.1097/AOG.0000000000002351
5. Macones GA, Hankins GD, Spong CY, Hauth J, Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol. 2008;112(3):661–666. doi:10.1097/AOG.0b013e3181841395
6. Lyndon A, Wisner K, eds; Association of Women’s Health, Obstetric and Neonatal Nurses. Fetal Heart Monitoring: Principles and Practices. 6th ed. Dubuque, IA: Kendall Hunt; 2021.
7. Magee LA, Smith GN, Bloch C, et al. Guideline No. 426: Hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547–571.e1. doi:10.1016/j.jogc.2022.03.002 (Supersedes the 2014 SOGC executive summary.)
8. Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195(4):914–934. doi:10.1016/j.ajog.2005.08.044
9. Roberts JM, Druzin M, August PA, et al. ACOG Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Washington, DC: ACOG; 2013.
10. World Health Organization, International Federation of Gynecology and Obstetrics, International Confederation of Midwives. Consolidated Guidelines for the Prevention, Diagnosis and Treatment of Postpartum Haemorrhage. Geneva: WHO; 2025. (Supersedes the 2012 WHO postpartum haemorrhage recommendations.)
11. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol. 2016;128(4):e155–e164. doi:10.1097/AOG.0000000000001711
12. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12(12):CD004454. doi:10.1002/14651858.CD004454.pub4 (Supersedes the 2017 Roberts edition.)
13. Duley L, Gülmezoglu AM, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. doi:10.1002/14651858.CD000025.pub2
14. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 229: Antepartum Fetal Surveillance. Obstet Gynecol. 2021;137(6):1134–1136. doi:10.1097/AOG.0000000000004411
15. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–622. doi:10.1056/NEJMoa1704559
16. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Guideline No. 10: Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management. Obstet Gynecol. 2025;146(4):583–599. doi:10.1097/AOG.0000000000006049 (Replaces Practice Bulletins No. 106 and 116.)
17. American College of Obstetricians and Gynecologists. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017;130(2):e102–e109. doi:10.1097/AOG.0000000000002237 (Interim update; reaffirmed 2024.)
18. Evensen A, Anderson JM, Fontaine P. Postpartum hemorrhage: prevention and treatment. Am Fam Physician. 2017;95(7):442–449.
19. Ford ND, Cox S, Ko JY, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization – United States, 2017–2019. MMWR Morb Mortal Wkly Rep. 2022;71(17):585–591. doi:10.15585/mmwr.mm7117a1